A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...
Dynavax should take a leaf from its vaccine maker peer, Novavax, and work to monetize its CpG1018 adjuvant. Learn more about ...
Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in ...
Discover the advantages of needle-free vaccines and which companies are developing their own promising delivery solutions in ...
The Danish group saw a further increase in sales of drugs to fight diabetes and obesity. In the US, Moderna shares lead the ...
Les quatre vaccins anti-COVID utilisés en France sont sûrs, réaffirme mardi 4 février l’agence du médicament dans son dernier ...
Healthcare was the only sector in the red by afternoon trading on the ASX, following a similar retreat on Wall Street ...
A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...
The VDH and Scott are advocating for people to get their vaccinations before winter. Scott said he has received his COVID ...
Robert F. Kennedy Jr., President Donald Trump's pick for health secretary, moved closer to securing the job on Tuesday, winning a recommendation from a congressional panel despite doubts about his ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback